Home/Filings/4/0000921895-23-000615
4//SEC Filing

Presight Sensei Co-Invest Fund, L.P. 4

Accession 0000921895-23-000615

CIK 0001829802other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 8:10 PM ET

Size

14.0 KB

Accession

0000921895-23-000615

Insider Transaction Report

Form 4
Period: 2023-02-23
Transactions
  • Purchase

    Common Stock

    2023-02-23$1.60/sh+1,100$1,7632,485,923 total(indirect: By Apeiron Investment Group Ltd.)
  • Purchase

    Common Stock

    2023-02-23$1.61/sh+1,100$1,7772,484,823 total(indirect: By Apeiron Investment Group Ltd.)
Holdings
  • Common Stock

    (indirect: By Presight Sensei Co-Invest Fund, L.P.)
    955,738
Transactions
  • Purchase

    Common Stock

    2023-02-23$1.61/sh+1,100$1,7772,484,823 total(indirect: By Apeiron Investment Group Ltd.)
  • Purchase

    Common Stock

    2023-02-23$1.60/sh+1,100$1,7632,485,923 total(indirect: By Apeiron Investment Group Ltd.)
Holdings
  • Common Stock

    (indirect: By Presight Sensei Co-Invest Fund, L.P.)
    955,738
Transactions
  • Purchase

    Common Stock

    2023-02-23$1.61/sh+1,100$1,7772,484,823 total(indirect: By Apeiron Investment Group Ltd.)
  • Purchase

    Common Stock

    2023-02-23$1.60/sh+1,100$1,7632,485,923 total(indirect: By Apeiron Investment Group Ltd.)
Holdings
  • Common Stock

    (indirect: By Presight Sensei Co-Invest Fund, L.P.)
    955,738
Transactions
  • Purchase

    Common Stock

    2023-02-23$1.60/sh+1,100$1,7632,485,923 total(indirect: By Apeiron Investment Group Ltd.)
  • Purchase

    Common Stock

    2023-02-23$1.61/sh+1,100$1,7772,484,823 total(indirect: By Apeiron Investment Group Ltd.)
Holdings
  • Common Stock

    (indirect: By Presight Sensei Co-Invest Fund, L.P.)
    955,738
Footnotes (3)
  • [F1]This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  • [F2]Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.
  • [F3]Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest.

Issuer

Sensei Biotherapeutics, Inc.

CIK 0001829802

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001828422

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 8:10 PM ET
Size
14.0 KB